293 results found
Winston & Strawn LLP | USA | 20 Dec 2018
Roche Molecular Systems, Inc. v. Cepheid, No. 2017-1690 (Fed. Cir. Oct. 9, 2018)
The Federal Circuit affirmed the Northern District of California’s summary judgment finding that patent claims related to detecting Mycobacterium…
Bradley Arant Boult Cummings LLP | USA | 29 Oct 2018
Rules for Patenting Genetic Biomarkers Are Updated in Roche v. Cepeid
As the readers of this blog are no doubt aware, patenting DNA defined only by a naturally occurring nucleotide sequence was banned by the U.S. Supreme…
Banner Witcoff | USA | 31 May 2018
Can Challengers Now Attack Subject Matter Eligibility in Inter Partes Reviews?
The statute authorizing inter partes reviews (IPR) explicitly limits the grounds for cancellation to Sections 102 and 103 of the patent statute:…
Knobbe Martens | USA | 4 Apr 2018
23andMe Wins FDA Approval for Test to Detect BRCA Mutations
The U.S. Food and Drug Administration (FDA) recently authorized 23andMe to market its Personal Genome Service Genetic Health Risk Report for…
KISCH IP | South Africa | 6 Feb 2017
Patenting DNA: discovery or invention?
Scientists and patent lawyers have long disagreed over whether DNA is a patentable invention or a mere discovery. The Patents Act states that a patent shall not be granted "for any variety of animal or plant or any essentially biological process for the production of animals or plants, not being a micro-biological process or the product of such a process". However, there is no significant......
Blake, Cassels & Graydon LLP | Canada | 27 Oct 2016
Breveter le vivant : une question qui « gène »
Si la Cour suprême du Canada (CSC) a déjà commenté l’épineuse question de savoir si les gènes peuvent être brevetés, aucun tribunal canadien n’a…
DLA Piper | Australia | 29 Jul 2016
Australian Patent Office resolves a Myriad of uncertainties
In D'Arcy v Myriad Genetics Inc [2015] HCA 35 (D'Arcy v Myriad), the High Court of Australia unanimously held that the impugned claims of Myriad's…
DLA Piper | USA | 26 Jul 2016
FDA’s new Next Generation Sequencing Draft Guidance leaves fundamental questions unanswered: key points
The Food and Drug Administration has released a 25-page Draft Guidance document addressing FDA oversight of certain applications of Next Generation…
Foley & Lardner LLP | USA | 7 Jul 2016
CAFC Finds Cryopreservation Method Patent Eligible
The Federal Circuit ruled that the cryopreservation methods at issue in Rapid Litigation Mgmt. Ltd. v. CellzDirect Inc., are patent eligible under 35…
Foley & Lardner LLP | USA | 11 Apr 2016
Methods Exploiting Junk DNA May Be Useful But Lack Patent Eligibility
Striking another blow against patent eligibility in the field of biotechnology, the Federal Circuit agreed with the district court that methods that…
